Metreleptin for treating lipodystrophy
KEYWORDS: metreleptin, lipodystrophy, treatment, people, company, committee, clinical, liver, experts, partial, section, evidence, noted, partial lipodystrophy, baseline

40 kg, dose adjustments of 1.25 mg to 2.5 mg are allowed up to a maximum daily dose of 10 mg. 3.3 The most common treatment-emergent adverse events in metreleptin studies included weight loss, hypoglycaemia, fatigue, injection site reactions, neutralising antibodies, decreased appetite, nausea, headache, abdominal pain, menorrhagia and alopecia. For full details of adverse reactions and contraindications, see the summary of product characteristics. 3.4 The price of metreleptin per 11.3 mg vial (up to a 10 mg dose) is £2,335.00; per 5.8 mg vial (up to a 5 mg dose) is £1,167.50 and per 3 mg vial (up to a 2.8 mg dose) is £583.75 (excluding VAT; company's evidence submission). The company has a commercial arrangement (simple discount patient access scheme). This makes metreleptin available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount. 4 Consideration of the evidence The evaluation committee (see section 6) considered evidence submitted by Amryt, the views of people with the condition and those who represent them, clinical experts and NHS England, a review of this submission by the evidence review group (ERG),
